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The bromodomain and extraterminal domain (BET) protein family
are promising therapeutic targets for a range of diseases linked to
transcriptional activation, cancer, viral latency, and viral integra-
tion. Tandem bromodomains selectively tether BET proteins to
chromatin by engaging cognate acetylated histone marks, and the
extraterminal (ET) domain is the focal point for recruiting a range
of cellular and viral proteins. BET proteins guide γ-retroviral inte-
gration to transcription start sites and enhancers through bimodal
interaction with chromatin and the γ-retroviral integrase (IN). We
report the NMR-derived solution structure of the Brd4 ET domain
bound to a conserved peptide sequence from the C terminus of
murine leukemia virus (MLV) IN. The complex reveals a protein–
protein interaction governed by the binding-coupled folding of
disordered regions in both interacting partners to form a well-
structured intermolecular three-stranded β sheet. In addition, we
show that a peptide comprising the ET binding motif (EBM) of MLV
IN can disrupt the cognate interaction of Brd4 with NSD3, and that
substitutions of Brd4 ET residues essential for binding MLV IN also
impair interaction of Brd4 with a number of cellular partners
involved in transcriptional regulation and chromatin remodeling.
This suggests that γ-retroviruses have evolved the EBM to mimic a
cognate interaction motif to achieve effective integration in host
chromatin. Collectively, our findings identify key structural fea-
tures of the ET domain of Brd4 that allow for interactions with
both cellular and viral proteins.
NMR | protein–protein interaction | BET family transcription factor |
retroviral integration | ET binding motif (EBM)
The bromodomain and extraterminal domain (BET) family ofproteins (Brd2, 3, 4, and T) play central roles in regulating
cell fate (1). They have been implicated in diverse cellular phe-
nomena, including inflammation, obesity, spermatogenesis, cancer,
DNA damage repair, viral latency, and, more recently, γ-retroviral
integration site selection (2–8). Most of these functions have been
associated with its dual role as epigenetic reader and transcriptional
activator (1–4).
The BET family of proteins, as well as the extended BET
family (Brd1, 7, 8, and 9), is characterized by two N-terminal
bromodomains and the extraterminal (ET) domain, for which
the proteins are named; Brd4 is known to occur in two different
isoforms, with the longer variant containing a C-terminal motif
(9) (Fig. 1A). The dual bromodomains recognize and bind acety-
lated lysines on histone H3 and H4 tails on chromatin (9–11),
thereby tethering the protein and any associated factors to those
histone posttranslational modifications (PTMs). Whereas rec-
ognition of select histone marks is achieved through the bro-
modomains, the overall high-affinity binding to chromatin is the
result of cooperative binding to both its cognate PTMs and
nonspecific binding to DNA wrapped around mononucleosomes
through interaction with the conserved motifs A and B (12, 13).
The C-terminal domain of the long Brd4 isoform functions in
activation of RNA polymerase II via interactions with pTEFb
(positive transcription elongation factor) and cooperates with
the jumonji C-domain-containing protein 6 (JMJD6) in regu-
lating release of promoter-proximal pausing (14).
Brd4 also exhibits a range of pTEFb-independent functions.
Isoforms lacking the C-terminal motif have been shown to
function in DNA damage repair via interactions with compo-
nents of the condensin II chromatin remodeling complex (8).
Proteomics and knockdown experiments demonstrated that the
ET domain mediates transcriptional activation through recruitment
of several chromatin-modifying enzymes, including JMJD6, histone-
lysine N-methyltransferase NSD3 (NSD3), glioma tumor suppres-
sor candidate region gene 1 protein (GLTSCR1), ATPase family
AAA domain-containing protein 5 (ATAD5), and chromodo-
main helicase DNA-binding protein 4 (CHD4) (15). The in-
teraction with NSD3 underlies an aggressive midline carcinoma
resulting from a chromosomal translocation that fuses Brd4 with
nuclear protein in testes (16). Owing to their role in cell cycle
regulation and epigenetic sensing, as well as associations with a
range of disease states, the therapeutic potential of targeting
BET proteins with small molecule inhibitors is an area of intense
interest, most of which is centered on preventing chromatin
binding by the bromodomains (10, 11).
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In addition to recruiting chromatin host factors involved in
transcriptional regulation, the ET domain has been implicated as
the binding site for viral factors, including γ-2 herpesvirus latency-
associated nuclear antigen and murine leukemia virus (MLV)
integrase (IN) (12, 17–19). Analyses of MLV integration site
selection revealed preferential integration at regions enriched in
acetylated histone PTMs, such as transcription start sites (TSS)
and enhancers, implicating guiding by BET proteins through
bimodal interactions with nucleosomes and MLV IN (6, 12, 20–
22). Although solution structures of the isolated MLV IN
C-terminal domain and of the ET domain have been reported,
the structural determinations of their interaction have not. Mu-
tagenesis experiments have shown that a conserved sequence
motif from the extreme C terminus of MLV IN is responsible for
specific tethering to the ET domain (Fig. 1B, yellow) (12, 23),
and NMR studies of the MLV IN C-terminal domain revealed
that this region is unstructured, suggesting a “fly-casting” mecha-
nism for BET protein binding (23). Modifications to this region
compromise MLV IN binding to BET proteins and alter MLV
integration patterns (12, 23–25). In addition, the sequence of the
ET domain is highly conserved (Fig. S1), adopting a structure
that features three α helices connected by two loops (26), whereas
its mode of interaction with other protein factors has yet to be
established.
We determined the solution structure of a complex between
the Brd4 ET domain and a peptide comprising the conserved
C-terminal sequence from MLV IN. Upon binding, both protein
and peptide undergo binding-coupled folding to form an in-
termolecular β sheet and make an array of specific side-chain
interactions. We show that these features are important for
binding of host transcription factors to full-length Brd4, and that
the peptide serves as an effective inhibitor of at least some of
these interactions.
Results
Binding of ET Binding Motif to Brd4 ET.A peptide comprising the 17
conserved residues from MLV IN (Fig. 1C) is necessary and suffi-
cient for ET domain binding, with an apparent affinity of ∼160 nM
as measured by isothermal titration calorimetry (ITC) (Fig. 2A).
NMR titrations show that the ET binding motif (EBM) binds in
the slow-exchange regime, and that the interaction is coupled to
folding of both partners, as evident from large chemical shift per-
turbations and increase in resonance dispersion (Figs. 2 B and C
and 3B and Fig. S2). Furthermore, significant downfield chemical
Fig. 1. Domain maps of Brd4 (A) and MLV integrase (B); the ET-binding
motif (EBM) is at the extreme C terminus (yellow). (C) Weblogo (weblogo.
berkeley.edu/) of sequence conservation at the C terminus of γ-retroviral
integrases, with the EBM peptide used in these studies indicated below;
residues 390–405 are highly conserved. β strands formed upon binding the
ET domain are indicated by block arrows (see text).
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Fig. 2. Induced-fit binding between Brd4 ET domain and the MLV IN EBM. (A) Isothermal titration calorimetry of the ET–EBM interaction reveals high af-
finity, with Kd 159 ± 12 nM. (B)
1H-15N–correlation spectra of [U-15N]-Brd4 ET domain in the absence (black) and presence of unlabeled MLV IN EBM (red).
Resonances with large chemical shift perturbations (CSPs) are labeled with their amino acid assignment. (All backbone amide assignments and plot of CSPs are
shown in Fig. S2.) (C) One-dimensional 1H spectrum of the MLV EBM free (black) and bound to the ET domain, with protein signals suppressed by a [13C, 15N]
filter (blue). Peaks labels indicate well-dispersed signals in the bound peptide, blue labels for backbone signals and green for side-chain signals.
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shifts for several Hα spins in both the ET and EBM indicate
formation of a β sheet.
Solution Structure of the ET Domain–EBM Complex. We determined
the solution structure of [U-13C, 15N]-labeled Brd4 ET (600–678)
bound to unlabeled MLV integrase EBM (389–405) from dis-
tance and torsion angle restraints. Complete Brd4 ET backbone
assignments and 86% side-chain assignments were obtained using
standard triple-resonance NMR spectra. Most of the missing side-
chain assignments are due to spectral overlap of lysine resonances.
The unlabeled peptide 1H assignments were achieved to 88%
using 2D 13C/15N-filtered COSY, total correlation spectroscopy
(TOCSY), and NOESY (Fig. S3A); 817 distance restraints for Brd4
ET were obtained from 3D 13C-edited or 15N-edited NOESY
spectra, 174 distance restraints for the MLV IN EBM were
obtained from a 2D 13C/15N-filtered NOESY spectrum, and
277 intermolecular distance restraints were obtained from
3D 13C/15N-filtered (f1), 13C-edited, or 15N-edited (f3) NOESY
spectra. Torsion angle restraints were obtained from chemical
shift data using TALOS-N (Table S1).
The solution structure was well-defined with an all-heavy-atom
rmsd of 1.86 ± 0.20 Å for the complex (Fig. 3A). The Brd4 ET
domain retained three α helices observed in the spectra of the
free Brd4 ET domain. All helices displayed NOE patterns con-
sistent with helices including midrange αN(i,i+3), NN(i,i+2), and
αβ(i,i+3) NOEs. Helix α1 spans residues Y612 to K624, helix α2
spans residues G627 to R640, and helix α3 spans P661 to L675
(Fig. 3B).
The interface between the Brd4 ET domain and the MLV IN
peptide features a three-stranded antiparallel β sheet and con-
tacts involving helices α1 and α2, burying ∼780 Å2 of solvent-
accessible surface area on the ET domain. The newly formed β
sheet consists of one strand (β1) from the loop between helices
α2 and α3 of the ET domains and two strands from the MLV IN
peptide folding to form a β-hairpin (β6′, β7′); the sheet is well-
defined by NOEs characteristic of β−strand formation (Fig.
S3B). Interestingly, both the Brd4 ET domain loop region and
the C-terminal tail of MLV integrase are poorly structured on
their own (23, 26). Thus, in the context of the isolated domains,
induced fit folding of both components is required to form the
interface, which partly explains the large chemical shift pertur-
bations observed within this region of the Brd4 ET domain (Fig.
S2). The interface features both hydrophobic and electrostatic
interactions on opposite faces of the β sheet (Fig. 3 C and D).
The structural features in the ET–EBM interface provide a
strong rationale for the observed sequence conservation of the
extreme C terminus of the γ-retroviral integrases, mirroring the
high degree of sequence conservation of the ET domains. Paired
strands β1 and β7′ are characterized by a pattern of alternating
hydrophobic and charged amino acids. The exterior surface of
the sheet features complementary electrostatic interactions be-
tween the negatively charged side chains on the conserved
DEIDIDF(650–656) of the ET domain β1 and the positively
Fig. 3. Solution structure of the complex between Brd4 ET and MLV IN
EBM. (A) Ensemble of 20 lowest-energy structures of the complex between
the Brd4 ET domain (gray) and EBM (yellow). (B) Ribbon diagram of the
lowest-energy conformer; the new β sheet comprises antiparallel strands β1
from the ET domain (residues 650–654) and β6′ (391′–395′) and β7′ (400′–
404′) from the EBM (Fig. S3). The protein ribbon is colored according to
backbone amide shift perturbations (as quantified in Fig. S2). (C and D)
Electrostatic potential map of the binding interface between Brd4 ET and
the EBM, illustrating charged and hydrophobic residues in the intermolec-
ular interface (Fig. 4).
Fig. 4. Specific side-chain interactions between Brd4 ET and MLV IN EBM.
(A) Complementary arrangement of positively charged side chains on β7′ of
IN (blue) and negatively charged side chains of the ET domain (black); ET
domain residues mutated for binding studies are labeled in red. (B) Hydro-
phobic interface defined by conserved nonpolar side chains on Brd4 and
MLV IN. Label colors as in A. (C) Affinity capture assay shows that MLV IN
binds to WT FLAG-tagged Brd4 (1–720) (lane 4), but not mutants designed to
disrupt the ET–EBM interface, V634S/I652S and E653R/D655R (lanes 5 and 6).
No Brd4 is detected bound to the resin in the absence of GST-tagged MLV-IN
(lanes 1–3); lanes 7–9 are immunoblots of 1/10th of the protein loaded in
lanes 1–6. (D) The His-tagged Brd4 ET domain can bind NSD3 in the absence
(lane 3), but not in the presence, of the EBM peptide (lane 2), demonstrating
competition between the viral and host factors for ET binding. Lane 1 shows
the presence of NSD3 in the extract, lane 4 shows no cross-reactivity, and
lane 5 shows that NSD3 is not retained on the Ni resin in the absence of Brd4.
(E) The FLAG-tagged Brd4 can bind NSD3 in the absence (lane 1), but not in
the presence, of the EBM peptide (lane 2), demonstrating competition be-
tween the viral and host factors for ET binding. Lane 3 shows that NSD3 is
not retained on the Ni resin in the absence of Brd4.
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charged side chains on the conserved LKIRLTR(399′–405′) on
the EBM β7′ (Fig. 4A). Additionally, the buried side of the sheet
features favorable hydrophobic interactions involving residues
contributed by helices α1 and α2 and the strand β1 of the ET
domain (L630, V634, I652, I654, and F656) and both strands of
the EBM (W390′, V392′, L399′, I401′, and L403′) (Fig. 4B).
These structural features are consistent with previous biochemical
and mutagenesis studies. For example, mutation to Ala of MLV
INW390′, which is positioned directly below strand β6′ and makes
hydrophobic contacts to L630 and V634, shifts the integration
profile of MLV-based vectors away from TSS (24). Likewise, af-
finity capture experiments using MLV IN and Brd2 mutants
showed that ET residues corresponding to Brd4 ET L630, D655,
F656, and E666 (Brd2 residues L662, D687, F688, and E657) are
critical for interaction with γ-retroviral integrases (18).
ET Domain Residues Recognized by the EBM Are Also Important for
Brd4 Binding to Other Cellular Components. The importance of
observed intermolecular contacts in molecular recognition by
full-length Brd4 were validated by site-directed mutagenesis: In
affinity capture experiments, Brd4 E653R/D655R and V634S/
I652S mutants fail to bind MLV IN (Fig. 4C, lanes 4–6), con-
sistent with published findings with Brd2 (18). We also tested the
effect of these mutations on binding to host factors in 293T cells
by affinity capture and proteomic analysis of ectopically expressed
FLAG-tagged WT and mutant Brd4 (Fig. S4 and Dataset S1). The
proteomic data do not distinguish between direct and indirect
interactions, and overall peptide counts were observed to de-
crease between WT Brd4 and the mutants; however, proteins
previously identified as ET domain-interacting proteins, including
NSD3 (and related NSD2), ATAD5, GLTSCR1, and CHD4 (and
related CHD7) (14, 15), could be identified as binding partners of
WT Brd4 but neither mutant. In addition, similar profiles were
observed for many proteins not already known to bind Brd4 (as
itemized in thebiogrid.org/), consistent with the participation of
Brd4 in interactions with a variety of higher-order protein
complexes. Importantly, interactions with histone proteins were
largely unaffected by the mutations, indicating that mutations to
the ET domain do not prevent Brd4 binding to chromatin via its
N-terminal bromodomains. We conclude that the structural
features on the Brd4 ET domain that are recognized by MLV IN
are also important for host-factor binding, which suggest a
structural basis for the participation of BET proteins in a variety
of chromatin-centered transactions.
The EBM Peptide Competes with NSD3 for the Brd4 ET Domain. A
peptide comprising the MLV IN-derived EBM can displace in-
teractions with host factors that target the Brd4 ET domain.
Using affinity capture and antibody detection, we found that
NSD3 binds either the full-length Brd4 or the isolated ET do-
main in the absence of the peptide, whereas 10 μM EBM abol-
ishes the interaction (Fig. 4D, lanes 2 and 3, and Fig. 4E, lanes 1
and 2). This finding supports the hypothesis that the structural
features conserved in the ET domain-binding region of the
γ-retroviral integrases are representative of a more universal
mechanism of host-factor recruitment to chromatin by BET
proteins. Thus, the compact ET binding motif defined by the C
terminus of the MLV IN may comprise the key features of ET
domain recognition by both viral and host factors.
Discussion
We report the solution structure of a high-affinity complex formed
between the ET domain of Brd4 and the EBM, a peptide com-
prising the interaction region from MLV IN. The NMR studies
reveal that these components interact via binding-coupled folding,
in which regions that were poorly structured in isolation (23, 26)
fold to form a new three-stranded β sheet that generates com-
plementary pairing of charged and hydrophobic residues on both
molecules. In cells, interactions between Brd4 and MLV IN are
critical for the recruitment of the MLV preintegration complex
(PIC) to host chromatin during integration. The PIC is com-
posed of a multimer of IN stably bound to viral DNA ends with
additional viral and cellular proteins (27, 28), which then engages
with Brd4 and its associated cognate chromatin binding partners
(4). Although the NMR data do not directly inform whether the
interacting regions of Brd4 and IN are unstructured in the
context of the intact PIC, amino acid substitutions at the ET–
EBM interface abolish the interaction between the full-length
recombinant Brd4 and MLV IN proteins (Fig. 4C) and affect
MLV integration (18, 24). This suggests that the intricacy and
complementarity of the interface revealed by the NMR struc-
tures is responsible for their tight and specific binding.
The role of BET proteins in guiding MLV integration site
selection to TSS and enhancers through the recognition of acet-
ylated histone tails is comparable to the role of LEDGF/p75
guiding lentiviral integration toward active transcription units
through the H3K36me3 epigenetic mark (29–35). Although both
cellular proteins use a bimodal mechanism for interaction with
chromatin and retroviral IN, the structural details of these inter-
actions are very different. In the case of lentiviruses and LEDGF/
p75, a short interhelical loop of the integrase binding domain
(IBD) of LEDGF/p75 engages a cavity on the dimer interface of
two HIV-1 catalytic core domains (35, 36). The essential inter-
acting features of LEDGF/IBD and HIV-1 IN are not conserved
in the interaction between BET proteins andMLV IN. Instead, we
observe a tight interaction governed by the formation of an in-
termolecular three-stranded β sheet upon binding, with specificity
governed by a pattern of alternating hydrophobic and charged
amino acids on both interfaces.
These studies have implications for the use of MLV-based
vectors in gene therapy. MLV-based vectors have been curatively
used in human gene therapy for treatment of several genetic
deficiencies, including X-linked severe combined immune de-
ficiency, Wiscott–Aldrich syndrome, and X-linked chronic granu-
lomatous disease (36–40). However, a common feature of all of
these studies is that a significant number of patients subsequently
developed leukemia due to transcriptional up-regulation of proto-
oncogenes (41–43). Because BET proteins are the primary de-
terminants of MLV integration-site selection (6), structural
characterization of the ET–EBM complex allows us to better un-
derstand the mechanisms of γ-retroviral integration site selectivity.
The observation that EBM residues important for ET binding
are highly conserved (Fig. 1) and interact with highly conserved
sequences in the ET domains (Figs. 3 and 4 and Fig. S1) suggests
that γ-retroviruses have evolved to mimic a conserved native
protein–protein interaction through modification of its C ter-
minus, which is not essential for catalytic activity in vitro or in
cells (12, 37). Indeed, our site-directed mutagenesis and pro-
teomic experiments indicate that the structural features of Brd4
important for binding by MLV IN are also important for binding
to cellular proteins previously identified to interact with the
ET domain, including NSD3, ATAD5, GLTSCR1, and CHD4
(Dataset S1), suggesting common interaction determinants. A
similar theme of structural mimicry of chromatin-associated
proteins by integrases is observed in yeast, wherein retrotransposon
Ty5 IN guides integration to regions of silent chromatin via inter-
actions between its C terminus with the heterochromatin protein
Sir4, using the same site as that of the nuclear membrane associated
protein Esc1, although the structural details differ between Ty5 and
MLV IN (38, 39).
Our structural and binding studies suggest a means for in-
terfering with specific aspects of BET protein function. BET
proteins, and Brd4 in particular, have attracted intense interest
because of their pleiotropic functions in a range of human dis-
eases (40). Most of this effort has been focused on selectively
targeting the bromodomains of BET proteins with mimics of
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acetylated lysine to prevent their association with chromatin (41–
43). We show that a peptide comprising the EBM can compete
with the transcription factor NSD3 for binding to full-length
Brd4, highlighting the importance of the ET domain in the in-
teraction. Considering the compactness of the structural motif
represented by the EBM, and its high-affinity binding to the ET
domain, we imagine that small molecule ligands modeled after it
might find use for disrupting interactions between Brd4 and a
subset of its interacting partners implicated in cellular phe-
nomena that include transcriptional activation, cancer, viral la-
tency, and viral integration.
Experimental Procedures
Plasmids and Protein Purification. C-terminal FLAG-tagged human full-length
Brd4(1–720) (amino acids 1–720; NM_014299) were purchased from Origene
(6). Mutations in full-length FLAG-Brd4(1–720) were introduced using a
site-directed mutagenesis kit (Stratagene). His-Brd4(1–720) was generated
and purified as previously described (6). HEK293T cells were cultured in
Dulbecco’s modified eagle medium (Invitrogen), 10% (vol/vol) FBS (Invitrogen),
and 1% (vol/vol) antibiotic (Gibco) at 37 °C and 5% (vol/vol) CO2. All ectopic
expression plasmids were transfected into HEK293T cells using TransIT-2020
(Mirus). GST-MLV IN (amino acids 1–408) was generated and purified as
previously described (6).
Expression and Purification of Recombinant Isotopically Labeled Brd4 ET. The
Brd4 ET domain was expressed in Escherichia coli BL21(DE3) cells (Agilent)
grown in M9 minimal media supplemented with 1% (vol/vol) Eagle Basal
Vitamin Mix (Life Technologies, Gaithersburg, MD), containing 1 g/L
15N-ammonium chloride (Cambridge Isotope Laboratories, Inc.) and 2 g/L
13C-glucose (Cambridge Isotope Laboratories, Inc.) as sole nitrogen and
carbon sources, respectively. Cultures were grown at 37 °C to an optical
density of 0.70 at 600 nm and induced for 16 h at 37 °C by addition of
0.5 mM isopropyl-thio-β-D-galactopyranoside. Bacterial cells from 1 L of
culture were disrupted by sonication in buffer containing 20 mM sodium
phosphate, pH 7.0, 500 mM NaCl, 15 mM imidazole, one-half tablet of the
complete EDTA-free protease inhibitor (Roche), and 50 μM PMSF (Thermo
Scientific). The protein was purified using a 5 mL HisTrap HP (GE Healthcare)
using a gradient from 15 mM to 500 mM imidazole in 20 mM sodium phos-
phate, pH 7.0. The N-terminal hexahistidine tag was removed by tobacco etch
virus (TEV) protease digestion at 25 °C for 16 h, leaving five nonnative amino
acids (Gly-Ala-Ile-Ala-Met) on the N terminus and two nonnative amino acids
(Thr-Arg) on the C terminus. The protein was the purified from the hexahistidine
tag fragment and the TEV protease by a second pass through the 5-mL HisTrap
HP column, this time collecting the flow-through. Finally, the protein was puri-
fied by size-exclusion chromatography using HiLoad 16/60 Superdex 75 (GE
Healthcare) in 20 mM sodium phosphate, pH 7.0, 500 mM NaCl, and 5 mM DTT.
Purified Brd4 ET was exchanged into NMR buffer (20 mM d11-Tris, pH 7.0,
150 mM NaCl, and 5 mM d6-DTT) using a PD10 column (GE Healthcare).
Isothermal Titration Calorimetry. ITC was performed by titrating MLV IN EBM
(206 μM) into Brd4 ET (14.9 μM) in buffer containing 100 mM NaCl, 1 mM
DTT, and 20 mM Tris at pH 7.0. The titration was performed using a MicroCal
VP-ITC at 25 °C with 28 injections (5 μL for the first injection and 10 μL for all
subsequent injections) with 400 s between injections. The first injection was
discarded and the data were fit to a one-site model using the Origin version
7 software package (MicroCal). Best-fitted parameters were n = 1.07 ± 0.01,
ΔH = −4,040 ± 43.6 cal/mol, and Kd = 159 ± 12 nM.
NMR Structure Determination. [U-15N]- or [U-15N,13C]- Brd4 ET was concen-
trated to 0.4 mM in buffer containing 100 mMNaCl, 5 mM d6-DTT, and 20 mM
d11-Tris, pH 7.0. D2O was added to 10% (vol/vol) and DSS to 0.66 mM to the
NMR sample. Unlabeled peptide containing residues 389–405 of MLV inte-
grase (the EBM), obtained from Biomatrik, Inc., was suspended in water to
make 2 mM stock solution and then titrated into NMR samples. The for-
mation of the high-affinity protein–peptide complex, which is in slow
exchange on the NMR timescale, was monitored by 2D 1H-15N–correlated
spectra of the labeled Brd4 ET domain as well as by 1D 13C/15N-filtered
1H spectra of the unlabeled peptide.
Structural determination followed a well-established protocol using
multidimensional and triple-resonance experiments (44–46). All of the
datasets were recorded at 25 °C on Bruker Avance DRX-600, DRX-700, and
DRX-800 spectrometers equipped with a 5-mm triple-resonance cryoprobe
and z axis gradient. Data were processed with NMRPipe (47) and visualized/
analyzed with NMRViewJ (48).
For protein backbone assignments, 3D triple-resonance spectra HNCO,
HNCA, HN(CO)CA, HNCACB, and CBCA(CO)NH (44) were recorded on purified
[U-13C, 15N] Brd4 ET containing the uncleaved hexahistidine tag and TEV
protease site in complex with the MLV IN EBM. In addition, HNCA and HNCO
spectra were recorded on the complex of [U-13C, 15N] Brd4 ET after the removal
of the hexahistidine tag, bound to unlabeledMLV IN EBM: Only plasmid-encoded
residues adjacent to the linker exhibited differences. Complete backbone as-
signment (76 of 76 non-proline residues) was achieved using NMRViewJ aided
by Probabilistic Interaction Network of Evidence algorithm (49).
Aliphatic side-chain assignments of Brd4 ET domain were obtained from
3D 15N-edited TOCSY, HCCH-TOCSY, HBHA(CO)NH, and CC(CO)NH-TOCSY
(44) of [U-13C,15N] Brd4 ET in complex with the MLV IN EBM. Side-chain 1H
assignments were 74% complete; most of the missing assignments were due to
signal overlap of Lys side chains and nonstereospecific assignments of methylene
protons. Excluding these factors the side chains were assigned to 92%.
MLV IN EBM proton chemical shift assignments in the bound form were
obtained by analysis of 2D 13C/15N-filtered TOCSY (DIPSI2 with 60-ms mixing
time), double-quantum filtered COSY, and NOESY (250-ms mixing time) (50, 51)
spectra recorded on a peptide sample in complex with [U-13C, 15N] Brd4 ET,
resulting in 88% assignment of the nonlabile protons.
Intraprotein distance restraints were obtained from 3D 15N-edited NOESY
and 3D 13C-edited NOESY spectra recorded in water (44). Intrapeptide dis-
tance constraints were obtained from 2D 13C/15N-filtered NOESY (51). In-
termolecular NOEs were obtained from 3D 13C/15N-filtered (f1) 15N-edited
(f3) NOESY and 3D 13C/15N-filtered (f1), 13C-edited (f3) NOESY (44, 51). Some
of the NOESY data sets (3D 13C-edited NOESY, 3D 13C/15N-filtered (f1), 13C-
edited (f3) NOESY, 2D 13C/15N-filtered NOESY) were repeated with the ly-
ophilized sample reconstituted in D2O. NOESY cross-peaks were analyzed and
assigned using NMRViewJ, and NOEs were categorized into strong, medium,
and weak corresponding to upper restraint distances 3.5, 4.5, and 5.5 Å, re-
spectively. NOE-derived distance constraints were supplemented with torsion
angle restraints predicted by TALOS-N (52) and hydrogen-bond constraints
identified in the secondary elements. A total of 150 structures were generated
using CYANA 3.97 (53), from which an ensemble of the 20 structures having
the lowest CYANA target function was selected. The 20-structure ensemble
contained Ramachandran plot statistics of 88.7% of residues in the most fa-
vored regions, 10.1% in additionally allowed regions, 1.3% in generously
allowed regions, and 0.0% in disallowed regions (Table S1).
Mass Spectrometry-Based Proteomic Analysis. To identify cellular binding
partners of FLAG-Brd4(1–720) or FLAG-Brd4(1–720) mutants, nuclear extracts
of HEK293T cells containing ectopically expressed FLAG constructs were
bound to FLAG beads (Sigma) in 25 mM Tris (pH 8.0), 200 mM NaCl, 0.2%
Nonidet P-40, 2 mM β-mercaptoethanol, and 1× complete protease mixture
(Roche). Nuclear extracts were prepared using the NE-PER Nuclear and Cy-
toplasmic Kit (Thermo Scientific), and the extracts were allowed to bind to
the beads and were subjected to an additional two washes. The bound
proteins were separated by SDS/PAGE, and entire lanes were excised for in-
gel trypsin digestion, followed by analysis of the peptide fragments with a
hybrid LTQ Orbitrap (Thermo Scientific) equipped with a nanoelectrospray
ion source (Thermo Scientific) connected to an EASY-nLC. Raw data were
converted to Mascot Generic Format using ReAdW4Mascot2 (chemdata.nist.
gov/dokuwiki/doku.php?id=peptidew:start) and spectra were searched with
Mascot (v.2.2.06; Matrix Science) against the UniProt human sequences with
a 10-ppm precursor tolerance and 0.5-Da fragment ion tolerance. Mascot
results were loaded into Scaffold (v.3.00.06; Proteome Software) with a
protein probability threshold of 90%, a peptide probability threshold of
90%, and a minimum of two peptides per protein (Dataset S1). For proteins
that had (i) no hits in the background experiments, (ii) three or more hits
with the WT protein, and (iii) no hits with the mutant proteins, the number
of entries in the BioGrid database (thebiogrid.org/) are indicated.
Protein Affinity Capture (Pull-Down) Experiments. Interactions between
recombinant GST-MLV IN and ectopically expressed WT and mutant FLAG-
Brd4(1–720) (80 μg total protein) were monitored by affinity pull-down as-
says as previously described for FLAG-Brd3 (6) with detection by Western
blotting with anti-FLAG antibody (Abcam). Protein pull-downs were per-
formed with glutathione Sepharose 4B beads (GE Healthcare) with buffer of
50 mM Hepes, pH 7.5, 200 mM NaCl, 0.5% Nonidet P-40, 2 mM BME, and 1×
complete protease mixture (Roche). Competition between native NSD3, MLV
IN EBM, and recombinant His-Brd4 ET or ectopically expressed FLAG-Brd4(1–
720) was monitored by affinity pull-down using Ni Sepharose 6 fast flow
beads (GE Healthcare) or anti-FLAG resin (Sigma) with detection by Western
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blotting with anti-NSD3 antibody (Abcam) (12). Nuclear extracts of HEK293T
cells (80 μg total protein) were prepared as described above and added to
His-Brd4 ET (2 μM) with or without prebound MLV IN EBM (10 μM) or RIPA
extract of HEK293T cells (100 μg) with ectopically expressed FLAG-Brd4(1–
720) were incubated with or without MLV IN EBM (10 μM) before anti-FLAG
pull-downs. Pull-down buffer was 50 mM Tris, pH 7.5, 200 mM NaCl, 0.5%
Nonidet P-40, 2 mM BME, 20 mM imidazole, and 1× complete protease
mixture (Roche) or the same buffer minus imidazole and BME, respectively.
Note Added in Proof.While this manuscript was under review, Shen et al. (54)
showed that nonpolar residues in the ET domain, which we show here to be
involved in binding to MLV IN (L630, I654, and F656), are also critical for
binding to NSD3.
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